News >

Venetoclax Combo Reaches High CR Rate in Older AML Patients

Published: Wednesday, Dec 20, 2017

Andrew Wei, MBBS, PhD

Andrew Wei, MBBS, PhD
Two-thirds of older patients with acute myeloid leukemia (AML) achieved complete responses with the combination of venetoclax (Venclexta) and cytarabine, according to results from a phase I/II trial.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x